Moderna’s new COVID-flu vaccine saw “positive” results in a phase 3 trial, according to the vaccine developer.
Responses of those who received one dose of the vaccine were “found to be non-inferior versus the co-administered, routinely recommended, licensed comparators,” Moderna wrote in a press release.
According to Moderna CEO Stephane Bancel, combination vaccines may “improve compliance” with inoculation campaigns.
He said in a statement that combination vaccines “have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses.”
The vaccine showed an “acceptable tolerability and safety profile,” Moderna noted, although there were adverse side-effects.
Many of the adverse reactions to the combination vaccine were “grade 1 or 2 in severity” and were “consistent with the licensed vaccines used in the trial.”
The most frequently reported adverse reactions were “injection site pain, fatigue, myalgia and headache.”
American Faith reported that the U.S. FDA approved the development of an mRNA vaccine for respiratory syncytial virus (RSV) from Moderna.
The vaccine is designed for those aged 60 and older and targets “global public health threats.”
Moderna is also developing a bird flu vaccine.
